BM1087 Epstein Barr Virus / EBV Capsid Antigen (VCA gp160) antibody

See related secondary antibodies

Search for all "Epstein Barr Virus / EBV"

0.2 mg / €370.00

Quick Overview

Mouse anti Epstein Barr Virus / EBV 2E3


Product Description for Epstein Barr Virus / EBV

Mouse anti Epstein Barr Virus / EBV 2E3.
Properties: Capsid Antigen (VCA gp160)
Presentation: Purified
Product is tested for Frozen Sections, Enzyme Immunoassay, Immunocytochemistry/Immunofluorescence, Western blot / Immunoblot.

Properties for Epstein Barr Virus / EBV

Product Category Primary Antibodies
Quantity 0.2 mg
Synonyms HHV-4, HHV4
Presentation Purified
Applications C, E, ICC/IF, WB
Clonality Monoclonal
Clone 2E3
Host Mouse
Isotype IgG2a
Molecular weight 110 kDa (VCA glycoprotein), 150 kDa (non-glycosylated VCA major capsid antigen)
Shipping to Worldwide
PDF datasheet View Datasheet
Manufacturer Acris Antibodies GmbH
Material safety datasheet MSDS for Monoclonal Antibodies (de)

Datasheet Extract

EBV wild type
Property Capsid Antigen, VCA gp160
Application ELISA. 
Western Blot (1/100-1/1000).
Immunofluorescence: (1/50-1/500).
Background Epstein-Barr virus (EBV), also designated human herpesvirus 4 (HHV-4), is a member of the herpesvirus family and is one of the most common human viruses, infecting about 90% of the population. EBV infects only B lymphocytes and, though often asymptomatic, it can cause infectious mononucleosis, a disease characterized by fatigue, fever, sore throat and muscle soreness. The linear genome of EBV circularizes once it enters the cell and exists there as an episome. EBV may play a role in the development of both Burkitt lymphoma, a disease in which a tumor can form on the mandible or maxilla, and nasopharyngeal carcinoma, a tumor found in the upper respiratory tract, most commonly in the nasopharynx. The viral capsid antigen (VCA) of EBV is used as a marker for screening for viral infection as well as nasopharyngeal carcinoma, and many antigens from the viral capsid are used in diagnostic tests.
Concentration 1.0 mg/ml
Product Citations
Originator or purchased from resellers:
  1. Feng X, Zhang J, Chen WN, Ching CB. Proteome profiling of Epstein-Barr virus infected nasopharyngeal carcinoma cell line: identification of potential biomarkers by comparative iTRAQ-coupled 2D LC/MS-MS analysis. J Proteomics. 2011 Apr 1;74(4):567-76. doi: 10.1016/j.jprot.2011.01.017. Epub 2011 Feb 4. PubMed PMID: 21296196.
General Readings
  1. Luka J, Miller G, Jörnvall H, Pearson GR. Characterization of the restricted component of Epstein-Barr virus early antigens as a cytoplasmic filamentous protein. J Virol. 1986 Jun;58(3):748-56. PubMed PMID: 2422401. (Free PMC Article available)
  2. Goldschmidts WL, Ginsburg M, Pearson GR. Neutralization of Epstein-Barr virus-induced ribonucleotide reductase with antibody to the major restricted early antigen polypeptide. Virology. 1989 May;170(1):330-3. PubMed PMID: 2541553.
  3. Fan, J.A. 1990. Expression of the Epstein-Barr virus p150 viral capsid antigen in Escherichia coli for the use as antigen in diagnostic tests. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 11: 381-387.
  4. Gorgievski-Hrisoho M, Hinderer W, Nebel-Schickel H, Horn J, Vornhagen R, Sonneborn HH, et al. Serodiagnosis of infectious mononucleosis by using recombinant Epstein-Barr virus antigens and enzyme-linked immunosorbent assay technology. J Clin Microbiol. 1990 Oct;28(10):2305-11. PubMed PMID: 2172287. (Free PMC Article available)
  5. Ruf IK, Rhyne PW, Yang H, Borza CM, Hutt-Fletcher LM, Cleveland JL, et al. Epstein-barr virus regulates c-MYC, apoptosis, and tumorigenicity in Burkitt lymphoma. Mol Cell Biol. 1999 Mar;19(3):1651-60. PubMed PMID: 10022853. (Free PMC Article available, 10 images available)
  6. Tranchand-Bunel, D., et al. 1999. Detection of human antibodies using “convergent” combinatorial peptide libraries or “mixotopes” designed from a nonvariable antigen: application to the EBV viral capsid antigen p18. J. Pept. Res. 52: 495-508.
  7. Gan, Y.Y., et al. 2001. Epstein-Barr viral antigens used in the diagnosis of nasopharyngeal carcinoma. J. Biomed. Sci. 3: 159-169.
  8. Kantakamalakul, W., et al. 2001. Specific IgA antibody to Epstein-Barr viral capsid antigen: a better marker for screening nasopharyngeal carcinoma than EBV-DNA detection by polymerase chain reaction. Asian Pac. J. Allergy Immunol. 18: 221-226.
  9. Spender LC, Lucchesi W, Bodelon G, Bilancio A, Karstegl CE, Asano T, et al. Cell target genes of Epstein-Barr virus transcription factor EBNA-2: induction of the p55alpha regulatory subunit of PI3-kinase and its role in survival of EREB2.5 cells. J Gen Virol. 2006 Oct;87(Pt 10):2859-67. PubMed PMID: 16963743.
Storage Store undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer.
Avoid repeated freezing and thawing.
Shelf life: one year from despatch.
Affinity Chromatography on Protein A
Buffer System:
0.09% Sodium Azide
Liquid purified IgG fraction
This antibody recognises a 160 kDa VCA antigen in immunoblotting.
Does not react with CMV, ADV, VSZ, HSV or other EBV antigens.

Accessory Products

  • LinkedIn